US3720760A
(en)
|
1968-09-06 |
1973-03-13 |
Pharmacia Ab |
Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
EP0092918B1
(en)
|
1982-04-22 |
1988-10-19 |
Imperial Chemical Industries Plc |
Continuous release formulations
|
NZ207394A
(en)
|
1983-03-08 |
1987-03-06 |
Commw Serum Lab Commission |
Detecting or determining sequence of amino acids
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
DE3856559T2
(de)
|
1987-05-21 |
2004-04-29 |
Micromet Ag |
Multifunktionelle Proteine mit vorbestimmter Zielsetzung
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
WO1991005548A1
(en)
|
1989-10-10 |
1991-05-02 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
AU642932B2
(en)
|
1989-11-06 |
1993-11-04 |
Alkermes Controlled Therapeutics, Inc. |
Protein microspheres and methods of using them
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
DK0517895T3
(da)
|
1990-12-14 |
1997-04-07 |
Univ California |
Kimæriske kæder til receptorforbundne signaltransduktionsveje
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
NL9101953A
(nl)
|
1991-11-21 |
1993-06-16 |
Seed Capital Investments |
Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
|
EP1136556B1
(en)
|
1991-11-25 |
2005-06-08 |
Enzon, Inc. |
Method of producing multivalent antigen-binding proteins
|
CA2103887C
(en)
|
1991-12-13 |
2005-08-30 |
Gary M. Studnicka |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
EP0672142B1
(en)
|
1992-12-04 |
2001-02-28 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
AU3382595A
(en)
|
1994-07-29 |
1996-03-04 |
Smithkline Beecham Corporation |
Novel compounds
|
WO1996020698A2
(en)
|
1995-01-05 |
1996-07-11 |
The Board Of Regents Acting For And On Behalf Of The University Of Michigan |
Surface-modified nanoparticles and method of making and using same
|
DE69636312T2
(de)
|
1995-01-17 |
2007-06-06 |
The Brigham And Women's Hospital Inc., Boston |
Rezeptorspezifischer Transepithelealer Transport von Immunogenen
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
CA2230494A1
(en)
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics Inc. |
Composition for sustained release of an agent
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
WO1997033899A1
(en)
|
1996-03-14 |
1997-09-18 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule i
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
KR100497017B1
(ko)
|
1996-03-22 |
2005-11-29 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
고사유도분자ii
|
EP0945506B1
(en)
|
1996-12-26 |
2007-02-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Proteine avec une activite de suppression du vieillissement
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
US20020012961A1
(en)
|
1999-04-15 |
2002-01-31 |
Genentech, Inc. |
Fibroblast growth factor- 19
|
US20060246540A1
(en)
|
1997-08-26 |
2006-11-02 |
Ashkenazi Avi J |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20020042367A1
(en)
|
1997-11-25 |
2002-04-11 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
US20030113718A1
(en)
|
1997-09-17 |
2003-06-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
IL134968A0
(en)
|
1997-09-17 |
2001-05-20 |
Genentech Inc |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030049676A1
(en)
|
1997-09-17 |
2003-03-13 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6806352B2
(en)
|
1997-09-17 |
2004-10-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
CA2309541C
(en)
|
1997-11-03 |
2011-01-11 |
Human Genome Sciences, Inc. |
Vegi, an inhibitor of angiogenesis and tumor growth
|
US20020155543A1
(en)
|
1997-11-25 |
2002-10-24 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
US20050026832A1
(en)
|
1997-11-25 |
2005-02-03 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
US20040126852A1
(en)
|
1997-11-25 |
2004-07-01 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ES2532910T3
(es)
|
1998-04-02 |
2015-04-01 |
Genentech, Inc. |
Variantes de anticuerpos y fragmentos de los mismos
|
US20030185846A1
(en)
|
1998-09-16 |
2003-10-02 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2000060085A1
(en)
|
1999-04-02 |
2000-10-12 |
Millennium Pharmaceuticals, Inc. |
Fibroblast growth factor-20
|
US7390879B2
(en)
|
1999-06-15 |
2008-06-24 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US7129072B1
(en)
|
1999-08-30 |
2006-10-31 |
New York University |
Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
|
JP2001072607A
(ja)
|
1999-09-03 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
新規血管内皮機能改善法
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
WO2001018209A1
(en)
|
1999-09-10 |
2001-03-15 |
Curagen Corporation |
Fibroblast growth factor polypeptide and nucleic acids encoding same
|
US6797695B1
(en)
|
1999-10-22 |
2004-09-28 |
Kyoto University |
Human FGF-20 gene and gene expression products
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
JP2003516731A
(ja)
|
1999-11-18 |
2003-05-20 |
カイロン コーポレイション |
ヒトfgf−21遺伝子および遺伝子発現産物
|
JP4651893B2
(ja)
|
1999-11-19 |
2011-03-16 |
社団法人芝蘭会 |
新規ポリペプチド、新規dna、新規抗体および新規遺伝子改変動物
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
US20010044525A1
(en)
|
2000-01-05 |
2001-11-22 |
Conklin Darrell C. |
Novel FGF Homolog zFGF12
|
WO2001049849A1
(en)
|
2000-01-05 |
2001-07-12 |
Zymogenetics, Inc. |
Novel fgf homolog zfgf11
|
EP1246843A1
(en)
|
2000-01-05 |
2002-10-09 |
ZymoGenetics, Inc. |
Novel fgf homolog zfgf12
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
CA2398603A1
(en)
|
2000-02-15 |
2001-08-23 |
Amgen, Inc. |
Fibroblast growth factor-23 molecules and uses thereof
|
US20060160181A1
(en)
|
2000-02-15 |
2006-07-20 |
Amgen Inc. |
Fibroblast Growth Factor-23 molecules and uses thereof
|
US20020082205A1
(en)
|
2000-03-08 |
2002-06-27 |
Nobuyuki Itoh |
Human FGF-23 gene and gene expression products
|
WO2001066596A2
(en)
|
2000-03-08 |
2001-09-13 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
WO2001072957A2
(en)
|
2000-03-31 |
2001-10-04 |
Nobuyuki Itoh |
Fibroblast growth factor-like molecules and uses thereof
|
US20030065140A1
(en)
|
2000-04-03 |
2003-04-03 |
Vernet Corine A.M. |
Novel proteins and nucleic acids encoding same
|
JP2002112772A
(ja)
|
2000-07-10 |
2002-04-16 |
Takeda Chem Ind Ltd |
新規ポリペプチドおよびそのdna
|
ES2340662T3
(es)
|
2000-07-19 |
2010-06-08 |
Advanced Research And Technology Institute |
Factor de crecimiento de fibroblastos (fgf23) nuevo procedimiento para el uso.
|
EP1309685A2
(en)
|
2000-07-20 |
2003-05-14 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US6812339B1
(en)
|
2000-09-08 |
2004-11-02 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
US20070037165A1
(en)
|
2000-09-08 |
2007-02-15 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
US7164009B2
(en)
|
2000-09-15 |
2007-01-16 |
Genentech, Inc. |
Pro9821 polypeptides
|
EP1197755A1
(en)
|
2000-10-11 |
2002-04-17 |
Pepscan Systems B.V. |
Identification of protein binding sites
|
US7537902B2
(en)
|
2000-10-24 |
2009-05-26 |
Emory University |
Methods and kits using a molecular interaction between a Smurf-1 WW domain and LIM mineralization protein isoforms
|
IL139380A0
(en)
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
WO2002041911A2
(en)
|
2000-11-22 |
2002-05-30 |
Bayer Corporation |
Use of fgf-19 for inhibiting angiogenesis
|
US20020151496A1
(en)
|
2000-12-08 |
2002-10-17 |
Bringmann Peter W. |
Novel fibroblast growth factors
|
DE10100587C1
(de)
|
2001-01-09 |
2002-11-21 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
DE10100588A1
(de)
|
2001-01-09 |
2002-07-18 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
US20030100497A1
(en)
|
2001-06-20 |
2003-05-29 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
WO2003029456A1
(en)
|
2001-10-01 |
2003-04-10 |
Dyax Corp. |
Multi-chain eukaryotic display vectors and uses thereof
|
WO2003035842A2
(en)
|
2001-10-24 |
2003-05-01 |
Dyax Corporation |
Hybridization control of sequence variation
|
US20050107475A1
(en)
|
2002-03-21 |
2005-05-19 |
Jones Stacey A. |
Methods of using farnesoid x receptor (frx) agonists
|
US6987121B2
(en)
|
2002-04-25 |
2006-01-17 |
Smithkline Beecham Corporation |
Compositions and methods for hepatoprotection and treatment of cholestasis
|
JP2003334088A
(ja)
|
2002-05-22 |
2003-11-25 |
Pharma Design Inc |
ヒト由来の新規Klotho様タンパク質及びその遺伝子
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
KR20050004914A
(ko)
|
2002-06-07 |
2005-01-12 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
EP1545584A4
(en)
|
2002-09-18 |
2007-04-04 |
Lilly Co Eli |
METHOD FOR REDUCING MORBIDITY AND MORTALITY OF CRITICAL SICK PATIENTS
|
WO2004063355A2
(en)
|
2003-01-10 |
2004-07-29 |
Protein Design Labs, Inc. |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
|
JP2006240990A
(ja)
*
|
2003-05-15 |
2006-09-14 |
Kirin Brewery Co Ltd |
klothoタンパク質および抗klothoタンパク質抗体ならびにそれらの用途
|
CN1802167A
(zh)
|
2003-06-12 |
2006-07-12 |
伊莱利利公司 |
融合蛋白质
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
BRPI0416683A
(pt)
|
2003-12-10 |
2007-01-30 |
Lilly Co Eli |
muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
|
EP1751184B1
(en)
|
2004-05-13 |
2009-09-30 |
Eli Lilly And Company |
Fgf-21 fusion proteins
|
JP2006016323A
(ja)
|
2004-06-30 |
2006-01-19 |
Hiroshima Industrial Promotion Organization |
生理活性バイオマテリアル
|
EP1789443A1
(en)
|
2004-09-02 |
2007-05-30 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
WO2006028595A2
(en)
|
2004-09-02 |
2006-03-16 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
ZA200704338B
(en)
|
2004-10-29 |
2009-03-25 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
CA2586201A1
(en)
|
2004-11-03 |
2006-05-11 |
Almac Diagnostics Limited |
Transcriptome microarray technology and methods of using the same
|
JP2006158339A
(ja)
|
2004-12-09 |
2006-06-22 |
Kyoto Univ |
βKlotho遺伝子、Cyp7a1遺伝子、及びそれらの利用
|
US7655627B2
(en)
|
2004-12-14 |
2010-02-02 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
US20060275794A1
(en)
|
2005-03-07 |
2006-12-07 |
Invitrogen Corporation |
Collections of matched biological reagents and methods for identifying matched reagents
|
EP2083081A1
(en)
|
2005-07-22 |
2009-07-29 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with FGFR fusion proteins
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20090081658A1
(en)
|
2005-08-24 |
2009-03-26 |
Abdelmajid Belouchi |
Genemap of the human genes associated with crohn's disease
|
EP1987055A1
(en)
|
2006-02-10 |
2008-11-05 |
Dermagen AB |
Novel antimicrobial peptides and use thereof
|
US8168169B2
(en)
|
2006-08-09 |
2012-05-01 |
Mclean Hospital Corporation |
Methods and compositions for the treatment of medical disorders
|
CN101563597A
(zh)
|
2006-09-01 |
2009-10-21 |
美国菌种保藏中心 |
用于诊断和治疗2型糖尿病的组合物和方法
|
JP5570218B2
(ja)
|
2006-11-03 |
2014-08-13 |
ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Fgfr4抗体
|
EP2457997B1
(en)
|
2007-01-03 |
2016-08-31 |
NeoStem Oncology, LLC |
Stem cell growth media and methods of making and using same
|
MX2009010531A
(es)
|
2007-03-30 |
2009-11-26 |
Ambrx Inc |
Polipeptidos de fgf-21 modificados y usos de los mismos.
|
EP2550972B1
(en)
|
2007-04-02 |
2018-02-21 |
Genentech, Inc. |
A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
|
JP5187837B2
(ja)
|
2007-04-06 |
2013-04-24 |
独立行政法人産業技術総合研究所 |
補助因子による受容体の活性化方法並びにリガンド活性の利用方法
|
US7537903B2
(en)
*
|
2007-04-23 |
2009-05-26 |
Board Of Regents, The University Of Texas System |
FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
|
US10555963B2
(en)
|
2007-05-08 |
2020-02-11 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho protein and related compounds for the treatment and diagnosis of cancer
|
EP2152295B1
(en)
|
2007-05-08 |
2018-04-18 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Klotho protein and related compounds for the treatment of cancer
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
WO2009076478A2
(en)
|
2007-12-10 |
2009-06-18 |
The Johns Hopkins University |
Hypomethylated genes in cancer
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
US8420088B2
(en)
|
2008-01-28 |
2013-04-16 |
Novartis Ag |
Methods and compositions using FGF23 fusion polypeptides
|
US20090226459A1
(en)
|
2008-01-29 |
2009-09-10 |
Cold Spring Harbor Laboratory |
Role of fgf-19 in cancer diagnosis and treatment
|
NZ602702A
(en)
|
2008-03-19 |
2014-03-28 |
Ambrx Inc |
Modified fgf-21 polypeptides and their uses
|
US20110015345A1
(en)
|
2008-03-19 |
2011-01-20 |
Ambrx, Inc. |
Modified FGF-23 Polypeptides and Their Uses
|
AU2009226246A1
(en)
|
2008-03-21 |
2009-09-24 |
Podiceps B.V. |
Diagnostic of pre-symptomatic metabolic syndrome
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
FR2933702A1
(fr)
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
AU2009279806B2
(en)
|
2008-08-04 |
2015-04-30 |
Five Prime Therapeutics, Inc. |
FGFR extracellular domain acidic region muteins
|
SG195542A1
(en)
|
2008-10-10 |
2013-12-30 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
WO2010065439A1
(en)
|
2008-12-05 |
2010-06-10 |
Eli Lilly And Company |
Variants of fibroblast growth factor 21
|
US20120035105A1
(en)
|
2009-01-09 |
2012-02-09 |
Sdg, Inc. |
Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
|
US20100274362A1
(en)
|
2009-01-15 |
2010-10-28 |
Avner Yayon |
Cartilage particle tissue mixtures optionally combined with a cancellous construct
|
EP3581579A1
(en)
|
2009-02-03 |
2019-12-18 |
Amunix Pharmaceuticals, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
NZ596037A
(en)
|
2009-05-05 |
2013-10-25 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
WO2010129600A2
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
US8461111B2
(en)
|
2009-05-20 |
2013-06-11 |
Florida State University Research Foundation |
Fibroblast growth factor mutants having improved functional half-life and methods of their use
|
EP2437775A1
(en)
|
2009-06-04 |
2012-04-11 |
Novartis AG |
Fgf-21 for treating cancers
|
CN102802657A
(zh)
|
2009-06-11 |
2012-11-28 |
诺沃-诺迪斯克有限公司 |
用于治疗2型糖尿病的glp-1和fgf21组合
|
CA2764835A1
(en)
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
KR101952453B1
(ko)
|
2009-10-15 |
2019-02-26 |
제넨테크, 인크. |
수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
|
US8889621B2
(en)
|
2009-10-30 |
2014-11-18 |
New York University |
Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
|
SG177025A1
(en)
*
|
2010-06-21 |
2012-01-30 |
Agency Science Tech & Res |
Hepatitis b virus specific antibody and uses thereof
|
AU2010326024A1
(en)
|
2009-12-02 |
2012-07-05 |
Amgen Inc. |
Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
US20110312881A1
(en)
|
2009-12-21 |
2011-12-22 |
Amunix, Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
EP2359843A1
(en)
|
2010-01-21 |
2011-08-24 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
US20110195077A1
(en)
|
2010-01-29 |
2011-08-11 |
Novartis Ag |
Methods and compositions using fgf23 fusion ppolypeptides
|
MX2012011986A
(es)
|
2010-04-15 |
2013-03-05 |
Amgen Inc |
RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
|
WO2011130729A2
(en)
|
2010-04-16 |
2011-10-20 |
Salk Institute For Biological Studies |
Methods for treating metabolic disorders using fgf
|
JP2013533227A
(ja)
|
2010-06-08 |
2013-08-22 |
ノヴォ ノルディスク アー/エス |
Fgf21類似体および誘導体
|
JP6069198B2
(ja)
|
2010-07-20 |
2017-02-01 |
ノヴォ ノルディスク アー/エス |
N末端が修飾されたfgf21化合物
|
WO2012031603A2
(en)
|
2010-09-09 |
2012-03-15 |
Danish Medical Consults Aps |
Airway administration of angiogenesis inhibitors
|
WO2012040518A2
(en)
|
2010-09-22 |
2012-03-29 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
CN102464712A
(zh)
|
2010-11-11 |
2012-05-23 |
重庆富进生物医药有限公司 |
缺失型人成纤维细胞生长因子21变异体及其偶联物
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
EP2654774A4
(en)
|
2010-12-22 |
2015-07-01 |
Marcadia Biotech Inc |
METHOD FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS WITH GIP AND GLP-1 RECEPTOR ACTIVE PUCIDIDES ON GLUCAGON BASIS
|
JP5850435B2
(ja)
|
2010-12-24 |
2016-02-03 |
国立研究開発法人産業技術総合研究所 |
ヒトfgf19活性の正確で高感度な測定方法ならびにヒトfgf19活性の制御剤
|
EP2694092B1
(en)
|
2011-04-08 |
2017-01-04 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
WO2012140650A2
(en)
|
2011-04-12 |
2012-10-18 |
Hepacore Ltd. |
Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
|
JP2014513981A
(ja)
|
2011-05-10 |
2014-06-19 |
アムジエン・インコーポレーテツド |
FGFR1とβ−KLOTHOの相互作用を特異的に調節する化合物の同定方法
|
SI2710035T1
(sl)
|
2011-05-16 |
2017-07-31 |
F. Hoffmann-La Roche Ag |
Agonisti FGFR1 in tehnike njihove uporabe
|
US9574002B2
(en)
*
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
EP2718486A4
(en)
|
2011-06-08 |
2014-12-31 |
Denovo Biopharma Hangzhou Ltd Co |
METHODS AND COMPOSITIONS FOR PREDICTING THE ACTIVITY OF A RETINOID RECEPTOR X MODULATOR
|
US20140294820A1
(en)
|
2011-06-24 |
2014-10-02 |
University Of Miami |
Fibroblast growth factor receptor inhibition for the treatment of disease
|
HUE045629T2
(hu)
|
2011-07-01 |
2020-01-28 |
Ngm Biopharmaceuticals Inc |
Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
|
EP2548570A1
(en)
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
WO2013027191A1
(en)
|
2011-08-25 |
2013-02-28 |
Novartis Ag |
Methods and compositions using fgf23 fusion polypeptides
|
WO2013033452A2
(en)
|
2011-08-31 |
2013-03-07 |
Amgen Inc. |
Method of treating or ameliorating type 1 diabetes using fgf21
|
US9458214B2
(en)
|
2011-09-26 |
2016-10-04 |
Novartis Ag |
Dual function fibroblast growth factor 21 proteins
|
TWI593708B
(zh)
|
2011-09-26 |
2017-08-01 |
諾華公司 |
治療代謝病症之融合蛋白質
|
AR087973A1
(es)
|
2011-10-04 |
2014-04-30 |
Lilly Co Eli |
Variantes del factor 21 del crecimiento de fibroblastos
|
US8871908B2
(en)
|
2011-11-11 |
2014-10-28 |
Rinat Neuroscience Corp. |
Antibodies specific for Trop-2 and their uses
|
WO2013109856A2
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
WO2013131091A1
(en)
|
2012-03-02 |
2013-09-06 |
New York University |
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
|
JP2013194049A
(ja)
|
2012-03-23 |
2013-09-30 |
Kazuo Todokoro |
ヒト造血幹細胞を増幅させるための組成物及び方法
|
EP2834358A4
(en)
|
2012-04-02 |
2016-03-09 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
|
EP2844273B1
(en)
|
2012-04-16 |
2018-01-31 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Klotho variant polypeptides and uses thereof in therapy
|
EP2852398A1
(en)
|
2012-05-15 |
2015-04-01 |
Eli Lilly and Company |
Therapeutic uses of fibroblast growth factor 21 proteins
|
US9657075B2
(en)
|
2012-06-07 |
2017-05-23 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
US9474785B2
(en)
|
2012-06-07 |
2016-10-25 |
New York University |
Chimeric fibroblast growth factor 19 proteins and methods of use
|
US9464126B2
(en)
|
2012-06-07 |
2016-10-11 |
New York University |
Chimeric fibroblast growth factor 21 proteins and methods of use
|
TWI513705B
(zh)
|
2012-06-11 |
2015-12-21 |
Lilly Co Eli |
纖維母細胞生長因子21蛋白質
|
ES2632078T3
(es)
|
2012-06-11 |
2017-09-08 |
Eli Lilly And Company |
Variantes del factor de crecimiento de fibroblastos 21
|
BR112015000653A2
(pt)
|
2012-07-11 |
2019-11-05 |
Blueprint Medicines Corp |
compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
|
AR092076A1
(es)
|
2012-08-22 |
2015-03-18 |
Lilly Co Eli |
Proteinas homodimericas
|
PE20150648A1
(es)
|
2012-09-07 |
2015-05-25 |
Sanofi Sa |
Proteinas de fusion para el tratamiento de un sindrome metabolico
|
EP3798228A1
(en)
|
2012-11-28 |
2021-03-31 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
CN105008548B
(zh)
|
2012-12-27 |
2020-11-27 |
恩格姆生物制药公司 |
用于调节胆汁酸体内稳态以及治疗胆汁酸紊乱和疾病的方法
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
US9550820B2
(en)
|
2013-02-22 |
2017-01-24 |
New York University |
Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
|
WO2014152090A1
(en)
|
2013-03-14 |
2014-09-25 |
Georgetown University |
Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
CN105828833A
(zh)
|
2013-10-21 |
2016-08-03 |
萨克生物研究学院 |
突变的成纤维细胞生长因子(fgf)1及使用方法
|
AU2014342630B2
(en)
|
2013-10-28 |
2020-11-05 |
Ngm Biopharmaceuticals, Inc. |
Cancer models and associated methods
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
SG11201606018UA
(en)
|
2014-01-24 |
2016-08-30 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
AU2015277438B2
(en)
|
2014-06-16 |
2020-02-27 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
CA2964782A1
(en)
|
2014-10-23 |
2016-04-28 |
Ngm Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising peptide variants and methods of use thereof
|
WO2016073855A1
(en)
|
2014-11-07 |
2016-05-12 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
CA3003616C
(en)
|
2015-11-09 |
2020-07-28 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
EP3503882A4
(en)
|
2016-08-26 |
2020-07-29 |
NGM Biopharmaceuticals, Inc. |
METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
|
WO2018044778A1
(en)
|
2016-08-29 |
2018-03-08 |
NGM Biopharmaceuticals, Inc |
Methods for treatment of bile acid-related disorders
|